Dr. Pasquini is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9200 W Wisconsin Ave
# Froedter
Milwaukee, WI 53226Phone+1 414-805-4100Fax+1 414-955-0231
Education & Training
- Medical College of Wisconsin Affiliated HospitalsFellowship, Hematology and Medical Oncology, 2004 - 2005
- University of Utah HealthFellowship, Hematology and Medical Oncology, 2001 - 2004
- University of Miami/Jackson Health SystemResidency, Internal Medicine, 1998 - 2001
- OtherClass of 1996
Certifications & Licensure
- WI State Medical License 2004 - 2025
- UT State Medical License 2001 - 2008
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma Start of enrollment: 2009 Feb 01
- Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Start of enrollment: 2011 Jun 01
- MM CAR-T to Upgrade Response BMTCTN1902 Start of enrollment: 2022 Jan 05
Publications & Presentations
PubMed
- 86 citationsNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committ...Steven Z. Pavletic, Shaji Kumar, Mohamad Mohty, Marcos de Lima, James M. Foran
Biology of Blood and Marrow Transplantation. 2010-07-01 - 79 citationsInternational harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.Luciano J. Costa, Benjamin A. Derman, Susan Bal, Surbhi Sidana, Saurabh Chhabra
Leukemia. 2021-01-01 - 1 citationsMinimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Te...Marcelo C Pasquini, Paul K Wallace, Brent Logan, Manmeet Kaur, Joseph D Tario
Journal of Clinical Oncology. 2024-08-10
Journal Articles
- Narrowing the Gap for Hematopoietic Stem Cell Transplantation in the East-Mediterranean/African Region: Comparison with Global HSCT Indications and TrendsMarcelo Pasquini, Daniel Weisdorf, Nature
Abstracts/Posters
- Impact of Renal Dysfunction Measured By Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT)Marcelo C. Pasquini, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Datab...Marcelo C. Pasquini, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- De Novo and Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome: Similarities and Differences in SNP-Array Detected Chromosomal Aberrations in Pre-Tran...Marcelo C. Pasquini, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Friday Scientific Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- Center for International Blood & Marrow Transplant Research Celebrates 50 YearsApril 22nd, 2022
- Out-of-Spec CAR-T Appears Safe, Effective for Younger Patients with ALLJanuary 31st, 2022
- The IL-6 Antagonist Tocilizumab Is Associated with Worse Depression and Related Symptoms in the Medically IllJanuary 18th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: